This came after an interviewer broached the idea of that movie getting a sequel. Kebbell’s quick, humorous response: “I won’t be in it!”
His reasons for wanting the transfer were somewhat odd. He seemed notably more interested in his own character, the mad scientist/sorcerer/dictator Victor von Doom, getting to join the Marvel Cinematic Universe than the titular superhero team.
“Listen, Doom is an incredible bad guy, they just keep trying to force him into the Fantastic Four, you know?” he said. “They just need to move it out, ’cause he smashes up Thor and Iron Man, all them. They get wasted.”
While Doom does battle other heroes in the comics, he is forever tied to the Fantastic Four as their arch-nemesis. In particular he has an intense rivalry with Richard Reed, the team’s leader and one of the few people who can rival Doom’s own intelligence.
The 2015 Fanastic Four was a famously awful movie; created mostly so that Fox would not have to return the rights to Marvel, it changed numerous elements from the comics. Many feel it was trying to be more of a sci-fi/horror film than a superhero movie. The result was panned as boring and nonsensical. (Kebbell’s costume as Doctor Doom was also notably awful.)
Marvel Studio’s Kevin Feige recently noted that Fox was unlikely to sell their other major Marvel property, X-Men, back to Marvel Studios. Fans still hope that Fantastic Four, having been less profitable for Fox, may have a chance, though Feige also noted that Marvel has a very detailed plan in place even without such franchises.
In most cases, it has always been noted that work experience has played a major role in shaping a person’s success. This is evident with Jeanmarie Guenot whose professional experience helped her achieve the best in life. She has more than twenty years of experience when it comes to the biotechnology and pharmaceutical industry. In her career journey, she has had the opportunity of working with various companies at all stages both private and public. Her field of expertise and interest majorly lies in rebuilding and establishing companies. She is the CEO and president of one largest firm, Amphivena Therapeutics Inc, aimed at developing bifunctional antibody therapies.
Guenot began her career journey at Atlas Venture where she was responsible for managing capital investments while building life science firms. Her career in science started when she worked at Hoffmann-La Roche as a principal scientist. Through this, she got the opportunity of learning new things and interacting with people. As a principle scientist in Preclinical R&D, she was responsible for developing and discovering medicine used for inflammation, oncology and autoimmune diseases. Training is crucial especially when it comes to developing new drugs that are intended to be ingested to patients. With this in mind, Dr. Jeanmarie is well trained in medicinal and physical chemistry that enables her to focus on protein structure prediction, semi-empirical methods, and drug design.
Jeanmarie Guenot was responsible for founding and running SKS Ocular before she became the CEO, and president of Amphivena Therapeutics Inc. the SKS Ocular was a start-up ophthalmic firm that majorly focused on therapeutics for glaucoma, ocular inflammation, dry AMD and macular degeneration. She also had the opportunity of serving as a VP at PDL BioPharma and a business advisor for Hoffmann-La Roche.
Through holding these various positions, she got the required experience sharpening her skills. All that she has achieved was also through having a good educational background as she received her MBA from the University of Pennsylvania and her Ph.D. from the University of California. She firmly believes that through her involvement in medicine, she will get an opportunity of saving a patient’s life somewhere. Her core goal has always been to provide a healthy environment for patients while saving their life.